AAA
LENZ

Affinity Asset Advisors’s LENZ Therapeutics LENZ Stock Holding History

Affinity Asset Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$568K Hold
100,000
– – 0.03% 108
2026
Q1 		$915K Buy
+100,000
New +$1.4M 0.05% 101

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Affinity Asset Advisors's LENZ Position: Q2 2026 in Review

Affinity Asset Advisors held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 100,000 shares worth $568K. The position accounts for 0.03% of the portfolio, ranked #108.

Affinity Asset Advisors first reported a position in LENZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $915K in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Affinity Asset Advisors held 100,000 shares of LENZ Therapeutics worth $568K as of Q2 2026.
  • Affinity Asset Advisors left its LENZ Therapeutics share count unchanged in Q2 2026.
  • LENZ Therapeutics made up 0.03% of Affinity Asset Advisors's portfolio in Q2 2026, its #108 holding.
  • Affinity Asset Advisors first reported a position in LENZ Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Affinity Asset Advisors's LENZ Therapeutics position peaked at $915K in Q1 2026.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.